New Press Release, May, 2009
Neoventa Appoints New Vice President for USA
Reading, MA -- Neoventa Medical, Inc., a medical device company that has developed proprietary software that is used as an adjunct to electronic fetal monitoring to determine whether obstetrical intervention is warranted when there is increased risk of the fetus developing metabolic acidosis during labor and delivery, announced the appointment of Marilyn Lapidus as Vice President. Ms. Lapidus will focus on sales, marketing, and business development for the USA. "I am very pleased that we have been able to add an exceptionally talented professional to the management team at Neoventa," said Jan Stålemark, President and CEO. "Marilyn has spent the last 30+ years focused on the care of the mother and fetus. Her skills will complement our team's expertise as we position our company for growth in the United States."
Prior to joining Neoventa, Ms. Lapidus was Director of Marketing at GE Healthcare, Maternal Infant Care, in the Maternal Fetal Care segment. She brings a wealth of marketing, product development, clinical research, continuing education, business development, and sales experience to this position. Before its acquisition by GE, Ms. Lapidus was Director of Clinical and Scientific Affairs for Marquette Medical Systems, which had previously acquired Corometrics Medical Systems. She is recognized worldwide as an authority on maternal/fetal monitoring with three (3) publications and has frequently participated in seminars and symposia on high-risk obstetrics. Ms. Lapidus earned a JD from the University of Connecticut School of Law and a BS in Nursing from Boston University.
"Marilyn joins us at an important time in Neoventa's growth as a company. Her expertise in this market segment, and her skill set and personal relationships with so many of the key opinion leaders will be especially helpful to our strategy for business development and plans for growing our market share in the United States” stated Mr. Stalemark.